Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Freeline Therapeutics Holdings stock

Learn how to easily invest in Freeline Therapeutics Holdings stock.

Freeline Therapeutics Holdings is a biotechnology business based in the US. Freeline Therapeutics Holdings shares (FRLN) are listed on the NASDAQ and all prices are listed in US Dollars. Freeline Therapeutics Holdings employs 235 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Freeline Therapeutics Holdings stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – FRLN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Freeline Therapeutics Holdings stock price (NASDAQ: FRLN)

Use our graph to track the performance of FRLN stocks over time.

Freeline Therapeutics Holdings shares at a glance

Information last updated 2023-02-01.
Latest market close$0.62
52-week range$0.46 - $1.29
50-day moving average $0.56
200-day moving average $0.75
Wall St. target price$5.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.53

Buy Freeline Therapeutics Holdings stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Freeline Therapeutics Holdings stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Freeline Therapeutics Holdings price performance over time

Historical closes compared with the close of $0.62 from 2023-02-06

1 week (2023-01-31) 5.62%
1 month (2023-01-06) 25.51%
3 months (2022-11-07) -15.07%
6 months (2022-08-05) -28.90%
1 year (2022-02-07) -48.33%
2 years (2021-02-05) -96.42%
3 years (2020-02-03) N/A
5 years (2018-02-03) N/A

Freeline Therapeutics Holdings financials

Gross profit TTM $0
Return on assets TTM -50.15%
Return on equity TTM -90.95%
Profit margin 0%
Book value $1.06
Market capitalisation $35.9 million

TTM: trailing 12 months

Freeline Therapeutics Holdings share dividends

We're not expecting Freeline Therapeutics Holdings to pay a dividend over the next 12 months.

Freeline Therapeutics Holdings share price volatility

Over the last 12 months, Freeline Therapeutics Holdings's shares have ranged in value from as little as $0.46 up to $1.29. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Freeline Therapeutics Holdings's is 0.2933. This would suggest that Freeline Therapeutics Holdings's shares are less volatile than average (for this exchange).

Freeline Therapeutics Holdings overview

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. .

Frequently asked questions

What percentage of Freeline Therapeutics Holdings is owned by institutions?
Currently 58.412% of Freeline Therapeutics Holdings shares are held by institutions.
How many people work for Freeline Therapeutics Holdings?
Latest data suggests 235 work at Freeline Therapeutics Holdings.
When does the fiscal year end for Freeline Therapeutics Holdings?
Freeline Therapeutics Holdings's fiscal year ends in December.
Where is Freeline Therapeutics Holdings based?
Freeline Therapeutics Holdings's address is: Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
What is Freeline Therapeutics Holdings's ISIN number?
Freeline Therapeutics Holdings's international securities identification number is: US35655L1070

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site